ORSERDU (elacestrant) 345 mg film-coated tablet contains 400 mg of elacestrant dihydrochloride (approximately 345 mg of elacestrant free base).
ORSERDU (elacestrant) 86 mg film-coated tablet contains 100 mg of elacestrant dihydrochloride (approximately 86 mg of elacestrant free base).
Both tablet strengths contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (non-bovine), microcrystalline cellulose, and silicified microcrystalline cellulose. The
tablets also contain Opadry II Blue (polyvinyl alcohol, titanium dioxide, polyethylene glycol, FD&C Blue #1 and talc).
ORSERDU (elacestrant) - 345 mg and 86 mg
*The recommended dosage of ORSERDU is one 345 mg tablet
taken orally, once daily, with food.
* Dose interruption, reduction, or permanent discontinuation may be
required due to adverse reactions.
treatment of postmenopausal women or adult men, with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.